Priyanka Sharma, MD

Articles by Priyanka Sharma, MD

116 Impact of Neoadjuvant Chemotherapy (NACT) Response on Clinical Outcomes With Ribociclib (RIB) in HR+/HER2− EBC: A Subgroup Analysis From the Phase 3 NATALEE Trial

ByNicholas McAndrew,Stephen Chia,Fabio Puglisi,Yann Izarzugaza,Christian Schem, MD,Binghe Xu,Fanny Le Du,Priyanka Sharma, MD,Peter A. Fasching,Alejandro Rodriguez,Murat Akdere,Yogesh Chattar,Juan Pablo Zarate,Aditya Bardia, MD, MPH, FASCO

May 13th 2026

121 Five-Year Analysis of Distant Disease-Free Survival (DDFS) Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib (RIB) Plus a Nonsteroidal Aromatase Inhibitor (NSAI) in Patients With HR+/HER2− Early Breast Cancer (EBC)

BySara A. Hurvitz, MD,Michal Jarzab,Alistair Ring,Priyanka Sharma, MD,Ionut Temciuc,Huilin Hu,Murat Akdere,Juan Pablo Zarate,Denise A. Yardley, MD

May 10th 2026

18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources

ByRadhika Appaya,Sarah Sammons, MD,Priyanka Sharma, MD,Yara Abdou,VK Gadi, MD, PhD,Taavy A. Miller,Spencer S. Langerman,Dominick Latremouille-Viau,Annie Guerin,Carmine Rossi,Emily McGovern,Gary Sopher,Vamsi Bollu,Natalia Bolotova,Şerban R. Iorga,Liz Santarsiero,Susan Dent, MD

June 30th 2025

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

BySara A. Hurvitz, MD,Michal Jarzab,Montserrat Munoz Mateu,Erin Cobain,Jin Zhang,Arielle Medford,Alistair Ring,Priyanka Sharma, MD,Christian Schem, MD,Ionut Temciuc,Zheng Li,Juan Pablo Zarate,Denise A. Yardley, MD

June 26th 2025

23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

ByNicholas McAndrew,Stephen Chia,Fabio Puglisi,Aditya Bardia, MD, MPH, FASCO,Yann Izarzugaza,Christian Schem, MD,Binghe Xu,Fanny Le Du,Priyanka Sharma, MD,Karen Afenjar,Murat Akdere,Juan Pablo Zarate,Yogesh Chattar,Peter A. Fasching

June 23rd 2025

31 TIP TROPION-Breast03: Datopotamab Deruxtecan (Dato-DXd) ± Durvalumab vs Investigator’s Choice of Therapy (ICT) for Triple-Negative Breast Cancer (TNBC) with Residual Disease Following Neoadjuvant Therapy

ByAditya Bardia, MD, MPH, FASCO,Lajos Pusztai, MD, DPhil,Kathy S. Albain, MD,Kevin Kalinsky, MD, MS,Dawn Herman,William Barlow,Claudine Isaacs, MD,Micah Maxwell,Nadia Harbeck, MD, PhD,Priyanka Sharma, MD

April 27th 2023

The Use of Surgery and Radiotherapy as Treatment of Regional Nodes in Breast Cancer Patients

ByMelissa P. Mitchell, MD, PhD,Priyanka Sharma, MD

June 15th 2018

This article discusses the ways in which pathologic regional nodal status affects clinical decisions about locoregional and systemic treatment, reviews published literature and guidelines, and aims to provide a practical perspective on treatment approach in the face of a broad range of data and recommendations.

Priyanka Sharma, MD

Articles by Priyanka Sharma, MD

116 Impact of Neoadjuvant Chemotherapy (NACT) Response on Clinical Outcomes With Ribociclib (RIB) in HR+/HER2− EBC: A Subgroup Analysis From the Phase 3 NATALEE Trial

121 Five-Year Analysis of Distant Disease-Free Survival (DDFS) Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib (RIB) Plus a Nonsteroidal Aromatase Inhibitor (NSAI) in Patients With HR+/HER2− Early Breast Cancer (EBC)

18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

31 TIP TROPION-Breast03: Datopotamab Deruxtecan (Dato-DXd) ± Durvalumab vs Investigator’s Choice of Therapy (ICT) for Triple-Negative Breast Cancer (TNBC) with Residual Disease Following Neoadjuvant Therapy

The Use of Surgery and Radiotherapy as Treatment of Regional Nodes in Breast Cancer Patients

Latest Updated Articles

Trending on CancerNetwork

Predicting Severe Immune-Related Toxicities in Lung Cancer Immunotherapy

Recapping GI Cancer at ESMO 2026: Standout Data From Phase 1 to Phase 3

EU Approves T-DXd for HER2+ Early Breast Cancer With Residual Disease

Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma

Better Biomarkers Needed to Guide Neoadjuvant Chemoimmunotherapy in NSCLC